Management of Allergic Reactions to First-Line Anti-TB Drugs
While Philippines-specific guidelines are not available in the provided evidence, the standard approach involves immediate cessation of all suspected drugs, followed by sequential reintroduction using graded challenge protocols once symptoms resolve, prioritizing isoniazid first, then rifampicin, and finally pyrazinamide—with the offending drug permanently excluded if reactions recur.
Initial Response to Allergic Reaction
When a patient develops an allergic reaction during TB treatment:
Stop All Hepatotoxic Drugs Immediately If:
- Clinical hepatitis symptoms appear (vomiting, abdominal pain, jaundice)
- AST/ALT rises to 5× normal
- Bilirubin elevation occurs 1
Maintain Treatment Coverage
- For smear-positive or severely ill patients: Continue treatment with streptomycin and ethambutol (non-hepatotoxic alternatives) until symptoms resolve 1
- For non-infectious, stable patients: Treatment can be paused until recovery 1
- Ensure at least 2 drugs remain active to prevent resistance development 1
Type of Hypersensitivity Determines Management Strategy
Type I Immediate Hypersensitivity (Urticaria, Anaphylaxis)
Recent evidence shows this occurs in 3.5-7.8% of TB patients 2, 3:
Mild Reactions (Grade 1):
- Cutaneous symptoms only (rash, itching, flushing)
- Management: Symptomatic relief, consider same-day rechallenge after symptom resolution 4
Moderate Reactions (Grade 2):
- Urticaria, throat tightness, chest tightness
- Management: Rapid desensitization protocols 4
Severe Reactions (Grade 3-4):
- Bronchospasm, hypoxia, anaphylaxis
- Management: Immediate cessation of all drugs; desensitization under intensive monitoring 4
Type IV Delayed Hypersensitivity (DRESS, SJS/TEN)
- DRESS: Stop all drugs, supportive care, consider topical corticosteroids (systemic steroids debated) 5
- Stevens-Johnson/TEN: Immediate cessation of ALL medications (including HIV drugs if applicable) until complete resolution 4
Sequential Drug Reintroduction Protocol
Once patient is clinically stable and symptoms resolved, reintroduce drugs sequentially 1:
Order of Reintroduction:
- Isoniazid first (least likely culprit for hepatotoxicity)
- Rifampicin second
- Pyrazinamide last (most hepatotoxic)
Specific Dosing Schedule 1:
Isoniazid:
- Day 1-3: 50 mg daily
- Day 4-6: 300 mg daily (continue if no reaction)
Rifampicin (add after 2-3 days without reaction):
- Day 1-3: 75 mg daily
- Day 4-6: 300 mg daily
- Day 7+: 450 mg (<50 kg) or 600 mg (>50 kg)
Pyrazinamide (add last):
- Day 1-3: 250 mg daily
- Day 4-6: 1.0 g daily
- Day 7+: 1.5 g (<50 kg) or 2.0 g (>50 kg)
Monitor During Reintroduction:
- Daily clinical assessment
- Liver function tests with each drug addition
- Stop immediately if reaction recurs
Rapid Desensitization Protocols
For Type I immediate hypersensitivity where standard drugs must be continued, rapid desensitization has 95% overall success rate 6:
Key Points:
- Perform under direct medical observation
- Most breakthrough reactions (84%) are mild 6
- Pyrazinamide has highest breakthrough rate but also highest single-reaction success 6
- Multiple drug desensitization possible but requires careful sequencing 6, 3, 7
- Protocols typically use 6-8 steps per drug, administered every 2 days 4, 7
Risk Factors for Breakthrough Reactions:
- Early timing of initial reaction (within first week) 6
- Female sex (4× higher risk) 7
- Concomitant ethambutol breakthrough increases rifampicin reaction risk 6
Alternative Regimens When Drug Must Be Excluded
If pyrazinamide is the offending drug:
- Use 9-month regimen: Rifampicin + Isoniazid + Ethambutol (first 2 months) 1
If rifampicin or isoniazid cannot be used:
- Requires expert consultation for individualized longer regimen
- Consider second-line drugs based on drug susceptibility testing 8
- Must maintain at least 4 effective drugs to prevent resistance 8, 4
Critical Pitfalls to Avoid
Never reintroduce drugs without ensuring at least 2 other active drugs to prevent resistance during desensitization 1
Do not use fluoroquinolones as empiric broad-spectrum antibiotics in suspected TB—they can mask symptoms and delay diagnosis 9
Avoid premature rechallenge: Wait for complete symptom resolution and normalization of laboratory values 1
For severe cutaneous reactions (SJS/TEN, DRESS): Drug avoidance is mandatory; desensitization is contraindicated 10, 5
Document the specific culprit drug to guide future treatment decisions and prevent unnecessary drug exclusions 6, 2
Special Populations
HIV Co-infection:
- Higher risk of Type IV reactions 11
- When restarting after DRESS, restart all ART drugs simultaneously (after TB drugs established) to prevent HIV resistance 4
Pregnancy:
- All first-line drugs can be used (WHO recommends including pyrazinamide) 12
- Risk-benefit discussion essential for each drug
Drug-Resistant TB: